Verbatim response from Perplexity
The FDA has cracked down on mass-marketed, non-FDA-approved compounded GLP-1 drugs (such as semaglutide and tirzepatide) because the national drug shortage has ended and supply is now stable, removing the legal justification for creating "essentially copies" of approved medications[1][3]. The agency is restricting the active pharmaceutical ingredients (APIs) used in these bulk-compounded products and has issued warning letters to telehealth companies (including Hims & Hers) that falsely market these compounds as equivalent to FDA-approved drugs[6][8].
Who is still operating legally: Legally operating entities are state-licensed 503A compounding pharmacies that fill individualized, patient-specific prescriptions from licensed healthcare providers, provided they meet strict conditions[2][11].
- 503A Pharmacies (Legal): These facilities must compound medication for a specific patient based on a valid prescription where the doctor determines the compounded drug is medically necessary (e.g., unique dosage or formulation not commercially available)[2][12].
- New Restriction: As of April 2026, a 503A pharmacy can only compound an "essentially copy" product if it fills no more than four prescriptions of that specific preparation per calendar month[4][9].
- Requirements: They must use FDA-registered APIs, meet USP compounding standards, and cannot mass-produce or market to the general public[2].
- 503B Outshipping Facilities (Likely Unlawful for Bulk GLP-1s): The FDA is proposing to remove GLP-1s from the 503B bulk compounding list because there is no current clinical need for pharmacies to bulk compound them[10][14]. While the rule is not yet final (public comment ends July 30, 2026), the pathway for bulk compounding is effectively closing[7].
- Telehealth Companies & Unlicensed Sellers (Illegal): Companies that mass-market compounded GLP-1s, claim they are "generic" equivalents, or sell to the public without a valid, individualized prescription are facing enforcement actions, including seizure and injunctions[6][13][16].
Key Brands/Services to Note:
- Hims & Hers: Explicitly named by the FDA as a target for enforcement regarding misleading marketing of unapproved compounded GLP-1s[6].
- Traditional 503A Pharmacies: Look for your local pharmacy that is state-licensed and explicitly operates as a 503A facility; they remain the only legal avenue for compounded GLP-1s if you have a valid, individualized prescription from your doctor[2].
In short, if you have a personal prescription from a doctor for a specific need and a local 503A pharmacy fills it (under the 4-prescription/month limit for copies), it is legal. If you are buying compounded GLP-1s online from a telehealth platform for general weight loss without a specific medical justification, it is increasingly illegal and unsupported by the FDA.